Opportunity ID: 332454

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-HG-21-007
Funding Opportunity Title: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.172 — Human Genome Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Mar 30, 2021
Last Updated Date: Mar 30, 2021
Original Closing Date for Applications: Feb 01, 2023
Current Closing Date for Applications: Feb 01, 2023
Archive Date: Mar 09, 2023
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Public housing authorities/Indian housing authorities
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Independent school districts
Special district governments
Native American tribal organizations (other than Federally recognized tribal governments)
Private institutions of higher education
County governments
Native American tribal governments (Federally recognized)
State governments
Small businesses
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
City or township governments
For profit organizations other than small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: This Funding Opportunity Announcement (FOA) solicits R21 grant applications to innovate and develop the early stages of novel technologies that will enable greater than a one order of magnitude improvement in 1) DNA sequencing, and 2) methods for direct sequencing of the diversity of entire RNA molecules. Advances in genomics and more broadly in biomedical research have been greatly facilitated by cycles of technology innovation and disruption that have driven significant and sustained nucleic acid sequencing throughput and assembly quality increases combined with cost decreases and quality improvements. The goal now is to dramatically advance DNA sequencing and direct RNA sequencing technologies at reasonable costs with the anticipation that significant exploratory innovation in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRIs other technology development goals
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-007.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Folder 332454 Full Announcement-RFA-HG-21-007 -> RFA-HG-21-007-Full-Announcement.pdf

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Email: FBOWebmaster@OD.NIH.GOV
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-F Use for due dates on or before January 24, 2022 PKG00266265 May 26, 2021 Jan 24, 2022 View
FORMS-G Use for due dates on or before January 24, 2023 PKG00270340 Nov 16, 2021 Jan 24, 2023 View
FORMS-H Use for due dates on or after January 25, 2023 PKG00278177 Nov 08, 2022 Feb 01, 2023 View

Package 1

Mandatory forms

332454 RR_SF424_2_0-2.0.pdf

332454 PHS398_CoverPageSupplement_5_0-5.0.pdf

332454 RR_OtherProjectInfo_1_4-1.4.pdf

332454 PerformanceSite_2_0-2.0.pdf

332454 RR_KeyPersonExpanded_2_0-2.0.pdf

332454 PHS398_ResearchPlan_4_0-4.0.pdf

332454 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf

Optional forms

332454 RR_Budget_1_4-1.4.pdf

332454 RR_SubawardBudget30_1_4-1.4.pdf

332454 PHS398_ModularBudget_1_2-1.2.pdf

332454 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 2

Mandatory forms

332454 RR_SF424_5_0-5.0.pdf

332454 PHS398_CoverPageSupplement_5_0-5.0.pdf

332454 RR_OtherProjectInfo_1_4-1.4.pdf

332454 PerformanceSite_4_0-4.0.pdf

332454 RR_KeyPersonExpanded_4_0-4.0.pdf

332454 PHS398_ResearchPlan_4_0-4.0.pdf

332454 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

332454 RR_Budget_3_0-3.0.pdf

332454 RR_SubawardBudget30_3_0-3.0.pdf

332454 PHS398_ModularBudget_1_2-1.2.pdf

332454 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 3

Mandatory forms

332454 RR_SF424_5_0-5.0.pdf

332454 PHS398_CoverPageSupplement_5_0-5.0.pdf

332454 RR_OtherProjectInfo_1_4-1.4.pdf

332454 PerformanceSite_4_0-4.0.pdf

332454 RR_KeyPersonExpanded_4_0-4.0.pdf

332454 PHS398_ResearchPlan_5_0-5.0.pdf

332454 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

332454 RR_Budget_3_0-3.0.pdf

332454 RR_SubawardBudget30_3_0-3.0.pdf

332454 PHS398_ModularBudget_1_2-1.2.pdf

332454 PHS_AssignmentRequestForm_3_0-3.0.pdf

2025-07-09T20:55:53-05:00

Share This Post, Choose Your Platform!

About the Author: